Clinical trial
Intravenous Estramustine With Taxol in Hormone Refractory Prostate…
NCT00038168 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00038168 |
|---|---|
| Title | Intravenous Estramustine With Taxol in Hormone Refractory Prostate Adenocarcinoma |
| Official title | Phase I/II Study of Intravenous Estramustine Phosphate Combined With Taxol in Patients With Hormone Refractory Adenocarcinoma of the Prostate |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | Estramustine, Taxol |
| Enrollment | 14 |
| Start date | Jun 1, 2000 |
| Primary completion | Jan 1, 2003 |
| Completion | Jan 1, 2003 |
| First posted | May 30, 2002 |
| Last update posted | Aug 1, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: